Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus...
Saved in:
| Published in | Journal of Atherosclerosis and Thrombosis Vol. 26; no. 7; pp. 659 - 669 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Japan Atherosclerosis Society
01.07.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1340-3478 1880-3873 1880-3873 |
| DOI | 10.5551/jat.45799 |
Cover
| Abstract | Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress.Methods: A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period.Results: Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease.Conclusion: Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. |
|---|---|
| AbstractList | Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress.Methods: A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period.Results: Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease.Conclusion: Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress. Methods: A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period. Results: Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease. Conclusion: Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress.AIMCardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress.A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period.METHODSA randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period.Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease.RESULTSSerum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease.Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes.CONCLUSIONBezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the abundant data indicating slower progression of atherosclerosis with statins, studies on fibrates remain scarce. The aim of this study was thus to clarify the effect of bezafibrate on CAVI as well as on oxidative stress. A randomized, open-label, controlled study was performed. 66 hypertriglyceridemic patients with type 2 diabetes were assigned to two groups: bezafibrate (400 mg/day) group and eicosapentaenoic acid (EPA 1.8 g/day) group. Patients were administered the respective treatment for 12 weeks. CAVI, glycolipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs) were evaluated before and after the study period. Serum triglycerides (TG), remnant-like particle cholesterol (RLP-C), fasting plasma glucose, HbA1c and d-ROMs decreased, while HDL-cholesterol increased significantly in the bezafibrate group but did not change in the EPA group. The decreases in TG, RLP-C, HbA1c and d-ROMs were significantly greater in the bezafibrate group than in the EPA group. CAVI decreased significantly only in the bezafibrate group and the decrease was significantly greater in bezafibrate group than in EPA group. Simple regression analysis showed no significant relationship between the change in CAVI and changes in other variables. Multivariate logistic regression analysis identified high baseline CAVI, low HDL-cholesterol level, and bezafibrate administration as significant independent predictors of CAVI decrease. Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. These effects potentially have important beneficial health consequences in hypertriglyceridemic patients with type 2 diabetes. |
| Author | Watanabe, Yasuhiro Tanaka, Sho Oka, Rena Nakamura, Shoko Ohira, Masahiro Nagayama, Daiji Shimizu, Naomi Tatsuno, Ichiro Kawana, Hidetoshi Imamura, Haruki Shirai, Kohji Sato, Yuta Yamaguchi, Takashi Saiki, Atsuhito |
| Author_xml | – sequence: 1 fullname: Ohira, Masahiro organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Kawana, Hidetoshi organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Shimizu, Naomi organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Shirai, Kohji organization: Mihama Katori Clinic – sequence: 1 fullname: Tatsuno, Ichiro organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Nakamura, Shoko organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Oka, Rena organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Saiki, Atsuhito organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Watanabe, Yasuhiro organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Nagayama, Daiji organization: Nagayama Clinic – sequence: 1 fullname: Tanaka, Sho organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Imamura, Haruki organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Yamaguchi, Takashi organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center – sequence: 1 fullname: Sato, Yuta organization: Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30584220$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkU2P0zAQhi20iP2AA38A-QiH7Dp2nKQXUCkfu9IikFi4WhN70ro4Sdd2gPIv-Mc47VIB4uIZeZ55Z-z3lBz1Q4-EPM7ZuZQyv1hDPC9kNZvdIyd5XbNM1JU4SrkoUl5U9TE5DWHNmBBS8gfkWDBZF5yzE_LzJf6A1jYeItJ5h84OUxro3Ef0Fhz9GG3b9hjSVQgpoKHNli7AGztk8_6LQ_oZgh4deHrVG_xObU8vtxv00dul2-okY7Czmn6AaLGPgX6zcUVvEkI5fWWhwWngO3TOxjE8JPdbcAEf3cUz8unN65vFZXb9_u3VYn6dacnzmDUoy1obrfMih0rwsjUGJDRgapNzEIVuBOpSaOASSlFxaKomZ-2sYtoUhokz8nyvuxmbDo1Om3lwauNtB36rBrDq70pvV2o5fFVlyWdVIZPA0zsBP9yOGKLqbNDpFdDjMAbF85KJspZVmdAnf846DPntQwKe7QHthxA8tgckZ2ryWCWP1c7jxF78w2ob09cO05rW_bfjxb5jHSIs8aANPlrtcEfyUlXTses4VPQKvMJe_AL_QMUL |
| CitedBy_id | crossref_primary_10_1159_000537687 crossref_primary_10_5551_jat_51409 crossref_primary_10_3390_jcm11030768 crossref_primary_10_5551_jat_RV17043 crossref_primary_10_18632_aging_205707 crossref_primary_10_2147_VHRM_S351602 crossref_primary_10_3390_jcm12247734 crossref_primary_10_1016_j_jjcc_2021_07_011 crossref_primary_10_5551_jat_60343 crossref_primary_10_1016_j_heliyon_2024_e28284 crossref_primary_10_3389_fendo_2023_1260764 crossref_primary_10_5551_jat_61101 crossref_primary_10_5551_jat_63695 crossref_primary_10_1093_ckj_sfad131 |
| Cites_doi | 10.1016/j.atherosclerosis.2007.11.008 10.1016/j.orcp.2011.08.154 10.1016/S0140-6736(07)60527-3 10.1038/362801a0 10.1038/35013000 10.1161/01.CIR.0000126824.12785.B6 10.1186/1475-2840-11-140 10.1016/j.amjcard.2008.08.033 10.1001/jama.288.20.2579 10.1016/0021-9150(84)90171-0 10.1016/S0021-9150(03)00156-4 10.1016/j.atherosclerosis.2007.05.029 10.5551/jat.ED098 10.1007/s11883-003-0086-y 10.5551/jat.281 10.1016/j.atherosclerosis.2008.05.055 10.5551/jat.13.101 10.5551/jat.42440 10.1016/S0021-9150(00)00394-4 10.5551/jat.497 10.5551/jat.40691 10.5551/jat.31385 10.1161/01.HYP.26.3.485 10.1161/01.CIR.0000093660.86242.BB |
| ContentType | Journal Article |
| Copyright | 2019 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. 2019 Japan Atherosclerosis Society 2019 |
| Copyright_xml | – notice: 2019 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. – notice: 2019 Japan Atherosclerosis Society 2019 |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.5551/jat.45799 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1880-3873 |
| EndPage | 669 |
| ExternalDocumentID | PMC6629745 30584220 10_5551_jat_45799 article_jat_26_7_26_45799_article_char_en |
| Genre | Journal Article |
| GroupedDBID | --- .55 29J 2WC 53G 5GY 5VS AAFWJ ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 OVT P6G RJT RNS RPM RZJ TR2 X7M AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c521t-be568cdcc141a7326fdda5abad8d12a34cb3ec63ca25a6372ab7b10f970cd4d03 |
| ISSN | 1340-3478 1880-3873 |
| IngestDate | Thu Aug 21 18:26:06 EDT 2025 Fri Jul 11 01:56:26 EDT 2025 Mon Jul 21 05:58:19 EDT 2025 Tue Jul 01 02:27:11 EDT 2025 Thu Apr 24 23:03:46 EDT 2025 Wed Sep 03 06:30:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Cardio-ankle vascular index (CAVI) Arterial stiffness Bezafibrate Triglyceride |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c521t-be568cdcc141a7326fdda5abad8d12a34cb3ec63ca25a6372ab7b10f970cd4d03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6629745 |
| PMID | 30584220 |
| PQID | 2160368576 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6629745 proquest_miscellaneous_2160368576 pubmed_primary_30584220 crossref_primary_10_5551_jat_45799 crossref_citationtrail_10_5551_jat_45799 jstage_primary_article_jat_26_7_26_45799_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20190701 |
| PublicationDateYYYYMMDD | 2019-07-01 |
| PublicationDate_xml | – month: 7 year: 2019 text: 20190701 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Journal of Atherosclerosis and Thrombosis |
| PublicationTitleAlternate | JAT |
| PublicationYear | 2019 |
| Publisher | Japan Atherosclerosis Society |
| Publisher_xml | – name: Japan Atherosclerosis Society |
| References | 3) Miyata M. Noninvasive Assessment of Arterial Stiffness Using Oscillometric Methods: baPWV, CAVI, API, and AVI. J Atheroscler Thromb 2018; 25: 790-791 50) Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109: 2097-2202 46) Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP.; SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis. 2008; 197: 355-362 12) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339: 229-234 28) Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008; 197: 12-24 21) Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol. 2012; 11: 125 27) Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Sakurai M, Urabe T, Shimada K, Miyazaki T, Daida H, Hattori N. Age Stratification and Impact of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid Ratios in Ischemic Stroke Patients. J Atheroscler Thromb. 2018; 25: 593-605 16) Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart. J. 1998; 19 Suppl: M8-14 5) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I. Cardio-Ankle Vascular Index is Independently Associated with Future Cardiovascular Events in Outpatients with Metabolic Disorders. J Atheroscler Thromb 2016; 23: 596-605 14) Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 1984; 51: 241-249 18) Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis. 2003; 171: 1-13 31) Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta. 1993; 216: 113-123 43) Beltowski J, Wójcicka G, Mydlarczyk M, Jamorz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma peroxidase 1 (PON1) activity. J. Physiol. Pharmacol. 2002; 53: 463-475 44) Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002; 288: 2579-2588 38) Von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr. Atheroscler. Rep. 2003; 5: 139-145 9) Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int. J. Clin. Pract. 2011; 65: 1200-1201 36) Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J. Cardiovasc. Phamacol. 1998; 32 Suppl 3: S33-37 41) Kato T, Umeda A, Miyagawa K, Takeda H, Adachi T, Toyoda S, Taguchi I, Inoue T, Node K. Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function. Hypertens. Res. 2014; 37: 655-658 8) Yamanaka M, Sakuma M, Matsushita A, Tanaka S, Yamamoto Y, Asai T, Arai H. The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia. J Atherscler Thromb 2019; 26: 39-49 17) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N.; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J. Clin. Endocrinol. Metab. 2011; 96: 3448-3456 34) Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485-490 47) Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am. J. Cardiol. 2009; 103: 41-45 42) Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 45-51 4) Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13: 101-107 32) Hasegawa M. Fundamental research on human aortic pulse wave velocity. Jikei Medical Journal 1970; 85: 742-760 33) Migdalis IN, Gerolimou B, Kozanidou, G, Voudouris G, Hatzigakis SM, Petropoulos A. Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. Int. Angiol. 1997; 16: 258-261 15) Hitsumoto T, Iizuka T, Takahashi M, Yoshinaga K, Matsumoto J, Shimizu K, Kaku M, Sugiyama Y, Sakurai T, Aoyagi K, Kanai M, Noike H, Ohsawa H, Watanabe H, Shirai K. Relationship between insulin resistance and oxidative stress in vivo. J. Cardiol. 2003; 42: 119-127 29) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098 40) Nakajima A, Aoki Y, Shibata Y, Sonobe M, Terajima F, Takahashi H, Saito M, Taniguchi S, Yamada M, Nakagawa K. Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. Mod. Rheumatol. 2014; 24: 926-930 37) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Athroscler Thromb 2009; 16: 539-545 35) Yamashina A, Tomiyama H, Arai T, Koji Y, Yambe M, Motobe H, Glunizia Z, Yamamoto Y, Hori S. Nomogram of the relation of brachial-ankle pulse wave velocity with blood pressure. Hypertens. Res. 2003; 26: 801-806 6) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int. J. Clin. Pract. 2010; 64: 1796-1801 24) Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes. Care. 1998; 21: 641-648 19) Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421-424 45) Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part 1: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108: 1912-1916 13) Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K , Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes. Care. 2005; 28: 2901-2907 39) Ebisawa S, Kashima Y, Miyashita Y, Yamazaki S, Abe N, Saigusa T, Miura T, Motoki H, Izawa A, Ikeda U. Impact of endovascular therapy on oxidative stress in patients with peripheral artery disease. Circ. J. 2014; 78: 1445-1450 2) Singh RB, Mengi SA, Xu YJ, Ameja AS, Dhalla NS. Pathogenesis of atherosclerosis: A multifactorial process. Exp. Clin. Cardiol. 2002; 7: 40-53 11) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. J. Atherscler. Thromb. 2018; 25: 621-623 23) Totsuka M, Miyashita Y, Ito Y, Watanabe H, Murano T, Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis. 2000; 153: 175-179 1) Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809 48) Kitajima K, Miura S, Matsuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation. Atherosclerosis. 2009; 203: 75-81 51) Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc. Diabetol. 2012; 11: 29 30) Satoh N, Shimatsu A, Kotani K, Himeno A, Majima T, Yamada K, Suganami T, Ogawa Y. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens. Res. 2009; 32: 1004-1008 10) Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K. Eff 44 45 46 47 48 49 50 51 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
| References_xml | – reference: 49) Zahradka P, Wright B, Fuerst M, Yurkova K, Molnar K, Taylor CG. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 2006; 317: 651-659 – reference: 33) Migdalis IN, Gerolimou B, Kozanidou, G, Voudouris G, Hatzigakis SM, Petropoulos A. Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. Int. Angiol. 1997; 16: 258-261 – reference: 6) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int. J. Clin. Pract. 2010; 64: 1796-1801 – reference: 5) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I. Cardio-Ankle Vascular Index is Independently Associated with Future Cardiovascular Events in Outpatients with Metabolic Disorders. J Atheroscler Thromb 2016; 23: 596-605 – reference: 10) Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K. Effects of body weight reduction on cardio-ankle vascular index (CAVI). Obes. Res. Clin. Pract. 2013; 7: e139-e145 – reference: 44) Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002; 288: 2579-2588 – reference: 31) Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin. Chem. Acta. 1993; 216: 113-123 – reference: 2) Singh RB, Mengi SA, Xu YJ, Ameja AS, Dhalla NS. Pathogenesis of atherosclerosis: A multifactorial process. Exp. Clin. Cardiol. 2002; 7: 40-53 – reference: 4) Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13: 101-107 – reference: 25) Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 2005; 165: 1154-1160 – reference: 43) Beltowski J, Wójcicka G, Mydlarczyk M, Jamorz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma peroxidase 1 (PON1) activity. J. Physiol. Pharmacol. 2002; 53: 463-475 – reference: 39) Ebisawa S, Kashima Y, Miyashita Y, Yamazaki S, Abe N, Saigusa T, Miura T, Motoki H, Izawa A, Ikeda U. Impact of endovascular therapy on oxidative stress in patients with peripheral artery disease. Circ. J. 2014; 78: 1445-1450 – reference: 41) Kato T, Umeda A, Miyagawa K, Takeda H, Adachi T, Toyoda S, Taguchi I, Inoue T, Node K. Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function. Hypertens. Res. 2014; 37: 655-658 – reference: 3) Miyata M. Noninvasive Assessment of Arterial Stiffness Using Oscillometric Methods: baPWV, CAVI, API, and AVI. J Atheroscler Thromb 2018; 25: 790-791 – reference: 16) Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart. J. 1998; 19 Suppl: M8-14 – reference: 18) Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis. 2003; 171: 1-13 – reference: 19) Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421-424 – reference: 45) Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part 1: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108: 1912-1916 – reference: 35) Yamashina A, Tomiyama H, Arai T, Koji Y, Yambe M, Motobe H, Glunizia Z, Yamamoto Y, Hori S. Nomogram of the relation of brachial-ankle pulse wave velocity with blood pressure. Hypertens. Res. 2003; 26: 801-806 – reference: 17) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N.; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J. Clin. Endocrinol. Metab. 2011; 96: 3448-3456 – reference: 50) Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109: 2097-2202 – reference: 14) Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 1984; 51: 241-249 – reference: 13) Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K , Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes. Care. 2005; 28: 2901-2907 – reference: 29) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098 – reference: 48) Kitajima K, Miura S, Matsuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation. Atherosclerosis. 2009; 203: 75-81 – reference: 12) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339: 229-234 – reference: 47) Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am. J. Cardiol. 2009; 103: 41-45 – reference: 38) Von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr. Atheroscler. Rep. 2003; 5: 139-145 – reference: 40) Nakajima A, Aoki Y, Shibata Y, Sonobe M, Terajima F, Takahashi H, Saito M, Taniguchi S, Yamada M, Nakagawa K. Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. Mod. Rheumatol. 2014; 24: 926-930 – reference: 22) Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc. Diabetol. 2012; 11: 140 – reference: 20) Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferatoractivated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000; 275: 16638-16642 – reference: 51) Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc. Diabetol. 2012; 11: 29 – reference: 1) Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809 – reference: 21) Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol. 2012; 11: 125 – reference: 36) Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J. Cardiovasc. Phamacol. 1998; 32 Suppl 3: S33-37 – reference: 11) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. J. Atherscler. Thromb. 2018; 25: 621-623 – reference: 42) Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 45-51 – reference: 23) Totsuka M, Miyashita Y, Ito Y, Watanabe H, Murano T, Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis. 2000; 153: 175-179 – reference: 30) Satoh N, Shimatsu A, Kotani K, Himeno A, Majima T, Yamada K, Suganami T, Ogawa Y. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens. Res. 2009; 32: 1004-1008 – reference: 9) Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int. J. Clin. Pract. 2011; 65: 1200-1201 – reference: 46) Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP.; SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis. 2008; 197: 355-362 – reference: 7) Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009; 16: 621-626 – reference: 26) Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin. Chem. 2006; 52: 2036-2042 – reference: 27) Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Sakurai M, Urabe T, Shimada K, Miyazaki T, Daida H, Hattori N. Age Stratification and Impact of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid Ratios in Ischemic Stroke Patients. J Atheroscler Thromb. 2018; 25: 593-605 – reference: 24) Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes. Care. 1998; 21: 641-648 – reference: 34) Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485-490 – reference: 15) Hitsumoto T, Iizuka T, Takahashi M, Yoshinaga K, Matsumoto J, Shimizu K, Kaku M, Sugiyama Y, Sakurai T, Aoyagi K, Kanai M, Noike H, Ohsawa H, Watanabe H, Shirai K. Relationship between insulin resistance and oxidative stress in vivo. J. Cardiol. 2003; 42: 119-127 – reference: 32) Hasegawa M. Fundamental research on human aortic pulse wave velocity. Jikei Medical Journal 1970; 85: 742-760 – reference: 28) Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008; 197: 12-24 – reference: 8) Yamanaka M, Sakuma M, Matsushita A, Tanaka S, Yamamoto Y, Asai T, Arai H. The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia. J Atherscler Thromb 2019; 26: 39-49 – reference: 37) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Athroscler Thromb 2009; 16: 539-545 – ident: 2 – ident: 28 doi: 10.1016/j.atherosclerosis.2007.11.008 – ident: 39 – ident: 10 doi: 10.1016/j.orcp.2011.08.154 – ident: 12 – ident: 35 – ident: 51 – ident: 16 – ident: 31 – ident: 9 – ident: 49 – ident: 26 – ident: 41 – ident: 17 – ident: 29 doi: 10.1016/S0140-6736(07)60527-3 – ident: 1 doi: 10.1038/362801a0 – ident: 19 doi: 10.1038/35013000 – ident: 13 – ident: 30 – ident: 50 doi: 10.1161/01.CIR.0000126824.12785.B6 – ident: 22 doi: 10.1186/1475-2840-11-140 – ident: 47 doi: 10.1016/j.amjcard.2008.08.033 – ident: 44 doi: 10.1001/jama.288.20.2579 – ident: 14 doi: 10.1016/0021-9150(84)90171-0 – ident: 40 – ident: 43 – ident: 18 doi: 10.1016/S0021-9150(03)00156-4 – ident: 46 doi: 10.1016/j.atherosclerosis.2007.05.029 – ident: 33 – ident: 3 doi: 10.5551/jat.ED098 – ident: 38 doi: 10.1007/s11883-003-0086-y – ident: 24 – ident: 37 doi: 10.5551/jat.281 – ident: 48 doi: 10.1016/j.atherosclerosis.2008.05.055 – ident: 4 doi: 10.5551/jat.13.101 – ident: 8 doi: 10.5551/jat.42440 – ident: 20 – ident: 42 – ident: 23 doi: 10.1016/S0021-9150(00)00394-4 – ident: 36 – ident: 7 doi: 10.5551/jat.497 – ident: 11 – ident: 27 doi: 10.5551/jat.40691 – ident: 5 doi: 10.5551/jat.31385 – ident: 34 doi: 10.1161/01.HYP.26.3.485 – ident: 15 – ident: 32 – ident: 6 – ident: 45 doi: 10.1161/01.CIR.0000093660.86242.BB – ident: 21 – ident: 25 |
| SSID | ssj0033552 |
| Score | 2.3197126 |
| Snippet | Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the... Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the... Aim: Cardio-ankle vascular index (CAVI) reflects arterial stiffness and has been established as a useful surrogate marker of atherosclerosis. Contrary to the... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 659 |
| SubjectTerms | Arterial stiffness Bezafibrate Cardio-ankle vascular index (CAVI) Original Triglyceride |
| Title | Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus |
| URI | https://www.jstage.jst.go.jp/article/jat/26/7/26_45799/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/30584220 https://www.proquest.com/docview/2160368576 https://pubmed.ncbi.nlm.nih.gov/PMC6629745 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Atherosclerosis and Thrombosis, 2019/07/01, Vol.26(7), pp.659-669 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKghAXxJvykkEckFaB1nHi9FiWXQralsN2UW-R4zhttm2C2vTQ_Rf8Av4qM3YS0qWHhYvV2lMn6nyZzIznQcjbHvcUQKHrdHXMHa595fRYrJ1YRDwCc0x0GCYnD0f-4Jx_nXiTVutXI2ppU0Tv1eXevJL_4SrMAV8xS_YfOFtvChPwGfgLI3AYxmvx-KO-lAnau4VJD1lguj36UfsYp4mu8LMiTRIjzOzhrlU3j0wMqtPP5gt9-L0KRf2CdRPR_TEA03RVgNW-2CrYpgyft_VXy2S4sXXcfqoct0Ms61mUPoS_VV2jZeZruHsY03UZtbnKlxF-rQWPXMop9mYxGJJzbPNUO4Bm6apsnJ3PLurpkZzKLfzMRuenzYW5XG5MD6XDs1k-z5veDZNQVXk3rEAG-YL1f60Q1HvmSilu8-5LtIqGSPZtxfGrrwoPVEXTogB7egjbpGm3HPfoW3hyfnoajo8n4xvkJhPCxAF8ntQxRC4oa-Y4vbohW7oKt_5Qb7yj8Ny6AJ1_qveZM1ejchtqzvgeuVsyjfYt2O6Tls4ekNvDMgLjIfnZwBxtYI5WmKM15miFORptaRNztMIcNZijaUb3YY5WmKOIOYqYo4xWmKMV5h6R85Pj8dHAKdt6OAq7ZziR9vxAxUp1eVcKMB-SOJaejGQcxF0mXa4iVyvfVZJ50ncFk5GIup0E5IaKedxxH5ODLM_0U0Ldng8GfocnfodzIeJIsaDHEk8IraRKWJu8q_77UJU177H1yiIE2xfZFAKbQsOmNnlTk_6whV72EQWWgTVJ-ewbEuaHAgdDWq9g9iQIqzZ5XbE8BAmOx3Iy0_lmHTLs9O4HYPi3yRMLgXp7eBsHnLFOm4gdcNQEWB1-dyVLZ6ZKvO-znuDes2tc9zm58-fZe0EOitVGvwRdu4heGbz_BltF4uE |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bezafibrate+Ameliorates+Arterial+Stiffness+Assessed+by+Cardio-Ankle+Vascular+Index+in+Hypertriglyceridemic+Patients+with+Type+2+Diabetes+Mellitus&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Yamaguchi%2C+Takashi&rft.au=Shirai%2C+Kohji&rft.au=Nagayama%2C+Daiji&rft.au=Nakamura%2C+Shoko&rft.date=2019-07-01&rft.issn=1880-3873&rft.eissn=1880-3873&rft.volume=26&rft.issue=7&rft.spage=659&rft_id=info:doi/10.5551%2Fjat.45799&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon |